Open AccessThe red wine component ellagic acid induces autophagy and exhibits anti‐lung cancer activity in vitro and in vivo
Author(s) -
Duan Jing,
Zhan JiCheng,
Wang GuiZhen,
Zhao XinChun,
Huang WeiDong,
Zhou GuangBiao
Publication year - 2019
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.13899
Subject(s) - celastrol , autophagy , resveratrol , in vivo , pharmacology , ellagic acid , lung cancer , cancer cell , cancer research , chemistry , pi3k/akt/mtor pathway , programmed cell death , in vitro , cancer , biology , apoptosis , biochemistry , medicine , polyphenol , antioxidant , genetics , microbiology and biotechnology
Red wine consists of a large amount of compounds such as resveratrol, which exhibits chemopreventive and therapeutic effects against several types of cancers by targeting cancer driver molecules. In this study, we tested the anti‐lung cancer activity of 11 red wine components and reported that a natural polyphenol compound ellagic acid ( EA ) inhibited lung cancer cell proliferation at an efficacy approximately equal to that of resveratrol. EA markedly increased the expression of the autophagosomal marker LC 3‐II as well as inactivation of the mechanistic target of rapamycin signalling pathway. EA elevated autophagy‐associated cell death by down‐regulating the expression of cancerous inhibitor of protein phosphatase 2A ( CIP 2A), and CIP 2A overexpression attenuated EA ‐induced autophagy of lung cancer cells. Treating tumour‐bearing mice with EA resulted in significant inhibition of tumour growth with suppression of CIP 2A levels and increased autophagy. In addition, EA potentiated the inhibitory effects of the natural compound celastrol on lung cancer cells in vitro and in vivo by enhancing autophagy and down‐regulating CIP 2A. These findings indicate that EA may be a promising chemotherapeutic agent for lung cancer, and that the combination of EA and celastrol may have applicability for the treatment of this disease.